Session Title: AMD I
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 10:06
Venue: Hall 1 (Level 2)
First Author: F.Holz GERMANY
To evaluate the real-world utilization and related outcomes of ranibizumab treatment for neovascular AMD in the first and second year of treatment.
Retrospective, international (Canada, France, Germany, Ireland, Italy, Netherlands, UK, Venezuela), observational study.
Consecutive neovascular AMD patients prescribed ranibizumab and started treatment between January 1, 2009 and August 31, 2009, were included, with a follow-up period of up to 2.5 years. Primary outcomes were change in visual acuity and resource utilization (number of treatment and monitoring visits, treatment use). Data presented as descriptive statistics.
In total 2671 patients were enrolled and 2227 patients were included in the effectiveness analysis set. Of these patients, follow up was documented for 1695 patients in the first year and 1184 in the second year. The mean (SD) age at diagnosis was 76.8 (8.2), majority of the patients were female (n = 1349 [60.6%]) and the main lesion types at diagnosis were occult (39.1%), classic choroidal neovascularization (28.2%) and classic and occult (11.6%). The mean (SD) visual acuity final score at baseline was 55.4 (18.4) and the mean (SD) change in visual acuity from baseline to Year 1 and 2 was 2.1 (16.6) and 2.1 (17.6) letters, respectively. The mean (SD) number of visits in Year 1 and 2 was 8.6 (3.3) and 4.9 (4.3), respectively and the mean (SD) number of monitoring visits was 3.4 (2.7) in Year 1 and 2.5 (2.6) in Year 2. The mean (SD) number of injections was 4.9 (2.4) in Year 1 and 2.1 (2.8) in Year 2.
Treatment with ranibizumab resulted in no observed change in visual acuity final score during the 2 years of ranibizumab treatment in patients with neovascular AMD in this study. The overall number of visits, monitoring visits and number of injections were lower in the second year than in the first year. Poorer than expected visual outcomes were due to less than monthly monitoring and low numbers of treatments per year. Although these results are better than untreated evolution of neovascular AMD, it is recommended that closer adherence to published protocols are followed and that patients with neovascular AMD are treated more aggressively in order to improve visual outcomes.